{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T18:24:49Z","timestamp":1792002289709,"version":"4.4.0"},"reference-count":12,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.ejca.2024.114204","type":"journal-article","created":{"date-parts":[[2024,7,5]],"date-time":"2024-07-05T21:03:57Z","timestamp":1720213437000},"page":"114204","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Sotorasib (960\u00a0mg or 240\u00a0mg) once daily in patients with previously treated KRAS G12C-mutated advanced NSCLC"],"prefix":"10.1016","volume":"208","author":[{"given":"Maximilian J.","family":"Hochmair","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karim","family":"Vermaelen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giannis","family":"Mountzios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enric","family":"Carcereny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Dooms","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Se-Hoon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Morocz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terufumi","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tudor-Eliade","family":"Ciuleanu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace K.","family":"Dy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Parente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth J.","family":"O\u2019Byrne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quincy S.","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilberto De","family":"Castro Junior","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Girard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Snyder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qui","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Kormany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett","family":"Houk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhakti","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Curioni-Fontecedro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2024.114204_bib1","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1158\/1078-0432.CCR-21-3074","article-title":"FDA approval summary: sotorasib for KRAS G12C-mutated metastatic NSCLC","volume":"28","author":"Nakajima","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2024.114204_bib2","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1917239","article-title":"KRAS(G12C) inhibition with sotorasib in advanced solid tumors","volume":"383","author":"Hong","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2024.114204_bib3","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1056\/NEJMoa2103695","article-title":"Sotorasib for lung cancers with KRAS p.G12C mutation","volume":"384","author":"Skoulidis","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2024.114204_bib4","doi-asserted-by":"crossref","first-page":"3311","DOI":"10.1200\/JCO.22.02524","article-title":"Long-term outcomes and molecular correlates of sotorasib efficacy in patients with pretreated KRAS G12C-mutated non-small-cell lung cancer: 2-year analysis of CodeBreaK 100","volume":"41","author":"Dy","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2024.114204_bib5","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/S0140-6736(23)00221-0","article-title":"Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRAS(G12C) mutation: a randomised, open-label, phase 3 trial.","volume":"401","author":"de Langen","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2024.114204_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/S1556-0864(23)00261-7","article-title":"7MO Sotorasib in KRAS G12C-mutated advanced non-small cell lung cancer (aNSCLC): overall survival (OS) data from the global expanded access program (EAP study-436)","volume":"18","author":"Novello","year":"2023","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ejca.2024.114204_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.113911","article-title":"Sotorasib in KRAS G12C-mutated non-small cell lung cancer: a multicenter real-world experience from the compassionate use program in Germany","volume":"201","author":"Stratmann","year":"2024","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2024.114204_bib8","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41586-019-1694-1","article-title":"The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity","volume":"575","author":"Canon","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.ejca.2024.114204_bib9","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1056\/NEJMoa2308795","article-title":"Sotorasib plus panitumumab in refractory colorectal cancer with mutated KRAS G12C","volume":"389","author":"Fakih","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2024.114204_bib10","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1144056","article-title":"Project Optimus, an FDA initiative: considerations for cancer drug development internationally, from an academic perspective","volume":"13","author":"Murphy","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.ejca.2024.114204_bib11","unstructured":"Project Optimus. Reforming the dose optimization and dose selection paradigm in oncology. Available at: https:\/\/www.fda.gov\/about-fda\/oncology-center-excellence\/project-optimus. Accessed 18 June 2024."},{"key":"10.1016\/j.ejca.2024.114204_bib12","unstructured":"Friends of Cancer Research White Paper. Optimizing dosing in oncology drug development. Friends of Cancer Research Annual Meeting 2021. Available at: https:\/\/friendsofcancerresearch.org\/wp-content\/uploads\/Optimizing_Dosing_in_Oncology_Drug_Development.pdf. Accessed 18 June 2024."}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804924008608?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804924008608?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T12:10:10Z","timestamp":1747656610000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804924008608"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":12,"alternative-id":["S0959804924008608"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2024.114204","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sotorasib (960\u00a0mg or 240\u00a0mg) once daily in patients with previously treated KRAS G12C-mutated advanced NSCLC","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2024.114204","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"114204"}}